** Shares of biotechnology company AbCellera Biologics Inc
ABCL.O up 9.9% premarket at $13.45
** Co late on Tuesday reported quarterly sales above market
estimates, mainly due to strong demand for COVID-19 antibody
drug bebtelovimab
** Bebtelovimab is the second COVID-19 antibody discovered
by ABCL and was licensed to Eli Lilly and Co LLY.N for
development, manufacturing and commercialization
** Q3 revenue of $101.38 mln beats estimates of $74.95 mln -
Refinitv IBES data
** Brokerage SVB Securities raises PT to $20 from $13 and
views co as "a promising antibody discovery platform" with
strong cash position to fund more programs to grow its pipeline
** Co has a cash position of $868 mln
** Up to Tuesday's close, stock had fallen ~15% YTD vs a
~12% decline in the Nasdaq Biotechnology index .NBI
(Reporting by Sriparna Roy)
((Sriparna.roy@thomsonreuters.com))